Schizophrenia remains a complex challenge that significantly impacts life expectancy and daily functioning. While dopamine-blocking agents have long been the standard of care, their limitations often leave patients with persistent symptoms. In this module, Dr. Christoph U. Correll explores the shortcomings of current therapies and discusses the latest efforts to optimize treatment strategies. Once you have completed this session, continue your learning journey by tuning into Module 2 to explore advances in long-acting injectables.

Note: This podcast expires on 2/17. Click the link below to claim your CME/NCPD/CPE credit.

bit.ly/432ICln